Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/polatuzumab-vedotin-boosts-survival-relapsed-dlbcl-2026a1000naz?src=rss
Author :
Publish date : 2026-07-09 12:48:00
Copyright for syndicated content belongs to the linked Source.
